Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 20/20 | 0.74 |
| ▸ | PPIB | P23284 | 19/20 | 0.74 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.71 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12946996 | 1.00 | PPIA (0.74) | PPIAPPIBSLCO1B1ABCB11ABCB1 | |
| SCHEMBL954752 | 1.00 | PPIA (0.74) | PPIAPPIBSLCO1B1ABCB11ABCB1 | |
| SCHEMBL958035 | 0.96 | PPIA (0.76) | PPIAPPIBSLCO1B1ABCB11ABCB1 | |
| SCHEMBL958036 | 0.96 | PPIA (0.76) | PPIAPPIBSLCO1B1ABCB11ABCB1 | |
| SCHEMBL952402 | 0.94 | PPIA (0.74) | PPIAPPIBSLCO1B1ABCB11ABCB1 | |
| SCHEMBL952403 | 0.94 | PPIA (0.74) | PPIAPPIBSLCO1B1ABCB11ABCB1 | |
| SCHEMBL952172 | 0.93 | PPIA (0.76) | PPIAPPIBSLCO1B1ABCB11ABCB1 | |
| SCHEMBL952174 | 0.93 | PPIA (0.76) | PPIAPPIBSLCO1B1ABCB11ABCB1 | |
| SCHEMBL954002 | 0.93 | PPIA (0.69) | PPIAPPIBSLCO1B1ABCB11ABCB1 | |
| SCHEMBL954003 | 0.93 | PPIA (0.69) | PPIAPPIBSLCO1B1ABCB11ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957518-B1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-8252895-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-7872097-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100286033-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. | 2010-11-11 | — | — | US | disclosed |
| US-20090170755-A1 | Cyclic Peptide Compounds | ASTELLAS PHARMA INC. (JP) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170755-A1 | Cyclic Peptide Compounds | VIP, HAVCR2, EIF2AK2 | PPIA 1681/4885PPIB 2157/4885SLCO1B1 4679/4885 |
| US-20100286033-A1 | NEW CYCLIC PEPTIDE COMPOUNDS | VIP, HAVCR2, EIF2AK2 | PPIA 1850/4885PPIB 2194/4885SLCO1B1 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.